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Abstract
Background: There are significant delays in initiation of multidrug-resistant tuberculosis (MDR –TB) treatment. The
Xpert MTB/RIF test has been shown to reduce the time to diagnosis and treatment of MDR-TB predominantly in
urban centres. This study describes the time to treatment of MDR-TB and the effect of Xpert MTB/RIF on time to
treatment in a deprived rural area in South Africa.
Methods: This was a retrospective cohort study analysing the medical records of patients diagnosed with MDR-TB in
King Sabata Dalindyebo Sub-District between 2009 and 2014. Numerical data were reported using the Kruskal-Wallis
and Wilcoxon sum rank tests and categorical data compared using the two-sample test of proportions.
Results: Of the 342 patients with MDR-TB identified, 285 were eligible for analysis, of whom 145 (61.4%) were
HIV positive. The median time from sputum collection to MDR-TB diagnosis was 27 days (IQR: 2–45) and
differed significantly between diagnostic modalities: Xpert MTB/RIF, 1 day (IQR: 1–4; n = 114: p < 0.0001); Line
Probe Assay 12 days (IQR: 8–21; n = 28; p < 0.0001); and culture/phenotypic drug sensitivity testing 45 days
(IQR: 39–59; n = 143: p < 0.0001). The time from diagnosis to treatment initiation was 14 days (IQR: 8–27) and
did not differ significantly between diagnostic modality. The median time from sputum collection to treatment
initiation was 49 days (IQR: 20–69) but differed significantly between diagnostic modalities: Xpert MTB/RIF,
18 days (IQR: 11–27; n = 114; p < 0.0001); Line Probe Assay 29 days (IQR: 14.5–53; n = 28; p < 0.0001); and
culture/phenotypic drug sensitivity, 64 days (IQR: 50–103; n = 143: P < 0.0001). Age, sex and HIV status
did not influence the time intervals.
Conclusions: Xpert MTB/RIF significantly reduced the time to MDR-TB treatment in a deprived rural setting as
a result of a reduced time to diagnosis. However, the national target of five days was not achieved. Further
research is needed to explore and address programmatic and patient-related challenges contributing to
delayed treatment initiation.
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Background
Isoniazid and Rifampicin (RIF) are still the cornerstones of
Tuberculosis (TB) chemotherapy. Resistance to both these
drugs defines multi-drug resistant TB (MDR-TB) [1].
While culture and in-vitro sensitivity testing is still the
reference standard for MDR-TB diagnosis, newer molecu-
lar diagnostic methods significantly reduce the time to
diagnosis. The World Health Organization endorsed the
Line Probe Assay (LPA) in 2008 [2] followed by the Xpert
MTB/RIF (Xpert) in 2010 [1]. Xpert is a cartridge based
nucleic acid amplification test that can identify both
Mycobacterium tuberculosis (MTB) and resistance to RIF
within 2 h of specimen processing. While Xpert identifies
RIF monoresistance, it is a proxy for MDR-TB [3, 4] and
patients are treated as such [5]. In South Africa, diagnosis
of MDR-TB was based on culture and phenotypic DST
until 2008 when the Department of Health adopted LPA
for smear positive sputum and culture isolates. Xpert
testing started in October 2011 [6] and replaced smear
microscopy as the initial test for both TB and MDR-TB
diagnosis [7].
In 2014, 5.9% of all TB notifications in South Africa
were MDR-TB [1]. However, only 62% of the estimated
18, 734 MDR-TB cases in 2014 were enrolled on
treatment and the treatment success rate for the 2012
cohort was 52% [1]. The high loss to follow-up may be
due to a high early mortality especially among HIV posi-
tive patients [8]. While the use of Xpert had not been
shown to reduce mortality [9] or morbidity [10] from
drug-sensitive TB, early treatment initiation in MDR-TB
is associated with a reduced time to culture conversion
[11, 12] and it is anticipated that early treatment will
reduce transmission.
The length of time for which the patient is infectious
has been implicated as a major factor in the spread of
the disease [7] while treatment renders patients rapidly
non-infectious [13]. This underscores the need for early
diagnosis and treatment.
The time-to-treatment initiation of MDR-TB (TTTI) is
defined as the period between sputum collection for drug
sensitivity testing and initiation of MDR-TB treatment.
The target TTTI is five days in South Africa [14]. Studies
have reported significant delays in TTTI depending on the
diagnostic modality. With the use of culture and pheno-
typic drug sensitivity testing (culture/phenotypic DST),
delays of 6 to 12 weeks have been reported [15, 16].
TTTI’s for LPA are between 18 and 62 days [11, 12, 17].
The shortest TTTI’s of 8 to 17 days [18–20] are associated
with Xpert, Xpert has a sensitivity of 95% and a specificity
of 98% for diagnosing RIF resistance in adults [21].
The impact of Xpert on TTTI to date has been evalu-
ated in urban settings [18–20]. The authors could not
find any study evaluating the effectiveness of Xpert on
TTTI in a rural setting in a developing country. The aim
of this study is to describe the TTTI and the effect of
the Xpert test on the TTTI among patients with MDR-




Time to diagnosis is the time (in days) from the day of
sputum collection to the day of issue of the diagnostic
laboratory report of Xpert, LPA or culture/phenotypic
DST to the clinic.
Time from diagnosis to treatment is the time taken
from the day of issue of the diagnostic laboratory report
to the day of initiation of MDR-TB treatment.
Time from sputum collection to MDR-TB treatment
is the time taken from the day of sputum collection to the
day of commencement of MDR-TB treatment.
This was a retrospective cohort study using medical
records of patients diagnosed with MDR-TB from Janu-
ary 2009 until December 2014.
Study setting
The study was conducted in the KSD Sub-District which
is one of four sub-districts in the OR Tambo District
Municipality. KSD has a total population of 451 710 [22]
which is predominantly rural. It is served by 49 primary
care facilities and three hospitals. OR Tambo Municipality
is the third most deprived district in South Africa [23]
with an estimated 59% of the population living below the
poverty line, a high unemployment rate of 44%, no access
to piped water for 51% of households, 70% living in
traditional dwellings, and 30% of households having no
electricity [22]. Rural residence is associated with reduced
access to health services in South Africa. In a community
survey, 66% of women in rural areas reported problems
with access to healthcare (mainly cost, distance and trans-
port) compared to 44% of urban women [24]. This is also
worsened by the fact that 44% of South Africa’s population
live in rural areas but are served by only 12% of doctors
and 19% of nurses [25].
Study population
The study population was all patients who were started
on MDR-TB treatment from January 2009 to December
2014 in KSD. All patients were admitted and initiated on
MDR-TB treatment in a designated TB hospital. As it
was not possible to ensure that all patients with MDR-
TB in KSD were identified through a review of medical
records, a sample size was calculated to ensure that the
number identified was sufficient for analysis.
South Africa had a MDR-TB prevalence of 5.9% (p = the
anticipated population proportion) in 2014. Using the 95%
confidence interval (z = 1.96) and a precision (d) of 3%,
the minimum sample size (n) was calculated using the
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following equation [26]: n = p(100-p)z2/d2. The minimum
sample size was 237 and a further 20% (~48) was added to
account for lost-to-follow up or data entry errors [27].
This yielded a sample size of 285 subjects using a purpos-
ive sampling method.
Data collection
Patients with MDR-TB from KSD were identified from
EDRWeb, a national electronic drug-resistant TB treat-
ment database with the following data elements: name,
sex, age, address, HIV and antiretroviral treatment
(ART), and date of treatment initiation. TB diagnostic
results were obtained from the National Health Labora-
tory Services (NHLS), patient files and private laborator-
ies. The date of diagnosis of MDR-TB was the date of
issue to the clinic of the diagnostic laboratory report by
Xpert, LPA or culture/phenotypic DST. The diagnosis of
MDR-TB was made on the initial diagnostic test result
after which a patient was initiated on treatment. Subse-
quent tests were not reported on in this study. A print-
out of results was obtained to ensure that the date of the
first report was captured correctly except for five results
where the date of issue was recorded in the patients’
files. Patients with extensively drug resistant (XDR-TB)
were also included as they were initially classified as
MDR-TB until the results of extended resistance testing
were available.
As it was not possible to obtain the dates of sputum col-
lection from facility registers (due to logistical challenges,
including many facilities over a wide area, poor gravel
roads and funding), the date of sputum registration at the
laboratory was taken as a proxy for the date of sputum
collection. There are daily (Monday to Friday) courier
collections to transport specimens from primary care
facilities to the hospital laboratories in the sub-district. All
patients had access to Xpert, TB culture and LPA. Xpert
was done in the two public hospitals and in the private
hospital laboratories. Specimens for TB culture were sent
to a centralised laboratory in KSD and those for LPA to a
provincial centre in Port Elizabeth.
Statistical analysis
Data were coded in Microsoft Excel 2010 (Microsoft
Corporation, Seattle, USA) and analysed using STATA
13.1 (Stata Corp LP, College Station, Texas, USA). To
analyse data that were not normally distributed, non-
parametric statistics (median, interquartile range (IQR),
the Wilcoxon sum rank test and the Kruskal-Wallis test)
were used. Categorical data were reported using propor-
tions and the 95% Confidence interval (95% CI) and
compared using the two-sample test of proportions.
Multinomial logistic regression was used to determine
predictors of “Time to Diagnosis” and “Time to Treat-
ment Initiation”. Both instances present outputs from
unadjusted models with all the variables and the ad-
justed model selected through the forward selection
process. The model with the lowest nested Aikaike’s
Information Criterion was selected as the better model.
The risk ratio was used to report on the extent of associ-
ations between the predictor variables and outcome. The
level of significance was set at 5% (p-value ≤ 0.05) and
the 95% CI was also used to report on the precision of
estimates.
Results
For the years 2009–2014, 342 records were found and
assessed for eligibility and exceeded the sample size
calculated.
Selection of study participants
Three hundred and forty-two patients were eligible for the
study, of which 57 (17%) were excluded for the following
reasons: no results were found for one patient; 22 were
excluded according to the study protocol as the interval
between the date of diagnosis and date of treatment
initiation exceeded one year (it was considered unlikely
that the decision to treat MDR-TB was based on a result
obtained a year or more earlier); and 34 had ‘negative
treatment start dates’ i.e. the date of treatment initiation
occurred before the date of diagnosis. A total of 285
participants were included in the study.
Table 1 shows patient characteristics and demographics.
There were significantly more males than females with
MDR-TB and HIV. All patients had pulmonary MDR-TB.
There were 279 sputum results from NHLS laboratories
and six from private laboratories. The majority of partici-
pants (74.4% or n = 212) were between the age of 18 and
50. Comparisons of the four age categories showed no
statistical difference in the proportion of participants in
those age category pairs (p < 0.001). There was also no
statistical difference between the proportion of partici-
pants who ranged from 18 to 35 years (39.3% or n = 112)
and those who were at least 35 years old but younger than
50 (n = 100 or 35.7%).
Figure 1 shows a map of the number of patients diag-
nosed with MDR-TB in each of the 52 healthcare facilities
in KSD. Each facility is numbered from 1 to 52 with the
number of patients with MDR-TB in brackets. The num-
ber of MDR-TB patients per facility ranged from 2 to 30
with a median of 4. Six facilities had no patient diagnosed
with MDR-TB. The map shows that patients were
diagnosed from all over the Sub-District. There is a
marked concentration of patients around Mthatha where
an academic hospital complex and a private hospital are
located.
Table 2 shows that overall; the median time to diagno-
sis was 27 days. The time to diagnosis was shortest for
Xpert (median = 1 day), was longer for LPA (median =
Iruedo et al. BMC Infectious Diseases  (2017) 17:91 Page 3 of 9
11.5 days) and longest for TB culture (median = 45 days).
Of 28 LPA tests, 15 were done on smear positive sputum
and 8 on culture isolates. Five sputum results were
documented in patient files without specifying them as
either a smear or a culture isolate. HIV negative patients
took significantly longer to be diagnosed with MDR-TB
(Median = 36-days) compared to HIV positive patients
(Median = 17-days). A chi-squared test, however, showed
HIV negative patients to be 15% more likely to have
been diagnosed by culture as compared to being
diagnosed by either Xpert or LPA but this was not
statistically significant; RR = 1.150 (95% CI: 0.913–1.449;
p-value = 0.242). In addition, there was no linear associ-
ation between age and the time to diagnosis (p = 0.912).
Table 3 shows that when those diagnosed after
12 days and those diagnosed within 3–12 days are
compared with those diagnosed in 2 days or less, it
was found that: in the unadjusted model, compared
to females, males were 89.3% more likely to be diag-
nosed after 12 days (RR: 1.893; 95% CI: 1.074–3.336)
and this was statistically significant (p-value: 0.027).
When this association was adjusted for the HIV status
the Risk Ratio marginally decreased (RR: 1.846; 95%
CI: 1.053–3.238) and was also statistically significant
Table 1 Patient characteristics and demographics
Sex n (%; 95% Confidence interval) p-value
Male 161 (56.5; 50.7–62.2)
Female 124 (43.5; 37.8–49.3) 0.0019
Total 285
AGE (Years) [category] n (%; 95% Confidence interval)
≤ 18 [a] 14 (4.9; 2.4–7.4) a vs b: <0.00001
19–34 [b] 112 (39.3; 33.6–45.0) a vs c: <0.00001
35–49 [c] 100 (35.1; 29.5–40.6) a vs d: <0.00001
≥ 50 [d] 59 (20.7; 16.0–25.4) b vs c: 0.298
b vs d: <0.00001
c vs d: 0.0001
Age (Years) by Sex Interquartile Range Median
Male 29–46 37
Female 26–48.5 34 0.1513
Total 27–48 36
HIV n (%; 95% Confidence interval)
Positive 175 (61.4; 55.8–67.1) <0.0001
Negative 110 (38.6; 32.9–44.2)
ARV Patients 175 (61.4; 55.8–67.1) <0.0001
Fig. 1 Number of patients diagnosed with MDR-TB per healthcare facility. The authors acknowledge permission from the Department of Health,
Eastern Cape Province, to use and adapt the map of health facilities in the King Sabata Dalindyebo Sub-District
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(p-value: 0.032). Age was not found to predict the
Time to Diagnosis.
Table 4 shows that the medians of the time it took for
patients to be initiated on treatment following diagnosis
were statistically similar suggesting that this time was
not dependent on the type of diagnostic test used. Even
when compared in pairs, all the diagnostic modalities
had statistically equal medians.
There was no linear association between age of patients
and the time it took for patients to start treatment. In the
multinomial regression, it was found that none of the
variables (age, sex, diagnostic modality, HIV status and
time to diagnosis) positively predicted the time to treat-
ment initiation.
Table 5 shows that the median time from sputum
collection to MDR-TB treatment initiation was 49 days.
However, when analysed by diagnostic modality, it was
significantly shortest for Xpert (18 days), was longer for
LPA (29 days) and longest for TB culture (64 days).
When compared in pairs, all the diagnostic modalities
had statistically different medians.
Predictors of the time from sputum collection to
treatment initiation
When those initiated on treatment after 70 days and those
initiated within 21–70 days were compared with those ini-
tiated in 20 days or less, it was found that: those diagnosed
with LPA as opposed to those diagnosed with culture were
74.2% less likely to be initiated on treatment after 70 days
as compared to being initiated on treatment on or before
20 days and this was statistically significant 0.258 (CI
0.071–0.936; p-value: 0.039) in the unadjusted model.
Similarly, the adjusted model showed a 73.3% less likeli-
hood 0.267 (CI 0.074–0.957; p-value: 0.043).
As compared to culture, those diagnosed with Xpert
were 4.56 times more likely to be initiated on MDR-TB
treatment between 21 and 70 days compared to being
initiated after 70 days and this was statistically signifi-
cant, RR = 4.560 (95% CI: 1.889–11.013; p-value = 0.001)
in the unadjusted model. The adjusted model showed a
marginal increase in the estimate where, RR = 4.563
(95% CI: 1.893–11.001; p-value: 0.001). Sex, HIV status
and age were not associated with TTTI.
Discussion
This study demonstrates the effectiveness (implementation
under real world conditions) of Xpert in a rural setting.
The results of this study show that the median TTTI was
significantly reduced with use of Xpert compared to LPA
and culture/phenotypic DST. The median TTTI of
18 days is similar to that of 16 days and 17 days in
two studies [18, 20] while a shorter TTTI of 8 days
was reported by Cox et al. [19], all conducted in
urban and peri-urban settings.
Table 2 Time to MDR-TB diagnosis (Days)
Variable Mode of MDR-
TB diagnosis
Number IQR Median p-value
Time to MDR TB
diagnosis (Days)
Culture 143 39–59 45
LPA 28 8–21 11.5 0.0001
Xpert 114 1–4 1
Total 285 2–45 27
HIV status Positive 175 2–43 17 0.0420




0.182 (−3.06–3.43) <0.0001 0.912
aA 10-year increase in age
Table 3 Predictors of the time to diagnosis (multinomial regression)
<=2 days 3–12 days >12 days
RR RR p-value RR p-value
Sex
Female (t) 1 0.665 (0.326–1.359) 0.263 0.528 (0.300–0.931) 0.027
Female (a) 1 0.673 (0.330–1.373) 0.277 0.542 (0.309–0.950) 0.032
Age (Years)
18 < Age < 35(t) 1 0.329 (0.056–1.953) 0.221 0.787 (0.147–4.197) 0.779
18 < Age < 35(a) 1 0.279 (0.049–1.582) 0.149 0.577 (0.112–2.977) 0.512
35≤ Age < 50(t) 1 0.263 (0.043–1.619) 0.150 0.845 (0.156–4.581) 0.845
35≤ Age < 50 (a) 1 0.218 (0.037–1.276) 0.091 0.595 (0.114–3.096) 0.538
≥ 50 (t) 1 0.305 (0.050–1.845) 0.196 0.487 (0.089–2.665) 0.407
≥ 50 (a) 1 0.293 (0.049–1.767) 0.181 0.456 (0.084–2.476) 0.363
HIV
Negative 1 1.394 (0.621–3.128) 0.421 1.894 (0.993–3.614) 0.053
t total unadjusted model, a model adjusted for HIV status
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The reduction in TTTI was due to a reduction in the
time to diagnosis, which was significantly shorter with
Xpert compared to LPA and culture/phenotypic DST.
This is similar to the study by Naidoo et al. [18] where
the time to diagnosis was reduced from 24 days with
LPA to 1 day with Xpert; and that of Van Kampen [20]
where the time to diagnosis was reduced from 75 days
with culture/phenotypic DST to 1 day with Xpert. How-
ever, Naidoo et al. [18] attributed 20% of the reduction
in TTTI to improved program management. Cox et al.,
[19] while not quantifying the contribution, also attrib-
uted their greatly improved TTTI of 8 days to both
implementation of a decentralized community-based
programme for drug-resistant TB, and the reduced time
to diagnosis from use of Xpert.
The time from diagnosis to treatment in this study did
not differ significantly between the three diagnostic mo-
dalities. Similar to this study, Hanrahan [11] and Jacobson
[17] did not find a reduction in median time from diagno-
sis to treatment comparing LPA to culture/phenotypic
DST. However, Naidoo et al. [18] reported a reduced
median time from diagnosis to treatment from 14 days
with LPA to 10 days with Xpert which was attributed to
better programme management.
Age and sex and HIV status had no influence on
TTTI, similar to the study by Naidoo et al. [18]. For time
from diagnosis to treatment, age and sex and HIV status
also had no influence. However, while age had no influ-
ence on time to diagnosis, males were significantly more
likely to be diagnosed after 12 days compared to females.
In South Africa, women utilize health care services more
than men [24] and may present earlier in the course of
illness. Patients with HIV were significantly likely to be
diagnosed faster compared to HIV negative patients
when using univariate analysis. However, multinomial
regression did not show any significant association be-
tween the HIV status and time to diagnosis. As HIV
positive patients typically have paucibacillary TB [28], it
is expected that it would actually take longer for them to
be diagnosed. The univariate analysis may have been
affected by confounding factors.
In this study, the median TTTI for LPA was also signifi-
cantly better compared to culture/phenotypic DST. This
result was expected as LPA technology has been shown to
improve TTTI mainly due to a reduction in time to diag-
nosis [11, 12, 17, 19]. In this study the median TTTI of
29 days for LPA was similar to that of 28 days in
Khayelitsha [19]. However, the time to diagnosis of
12 days was shorter than in the comparative studies
above. It is likely that this was because the majority
of LPA tests were done directly on smear positive
sputums and not on culture isolates. While Hanrahan
et al. [11] found an overall time to diagnosis of
26 days, the time to diagnosis was only 13 days when
LPA was done directly on smear positive sputums.
Other studies did not report separately on the results
of LPA done directly on sputum compared to culture
isolates [17, 18]. However, in this study, there were
few patients diagnosed with LPA. This may have been
due to the limited capacity for LPA testing in the
Eastern Cape Province. Furthermore, the number of
LPA results was too small for a meaningful statistical
analysis.
The studies from South Africa [11, 17–19], Georgia [12]
and Indonesia [20] consistently show a reduction in time
to diagnosis and TTTI when changing from older to
newer technologies. However, neither this study nor the
two published South African studies on the effectiveness
of Xpert [18, 19] met the target for TTTI of five working
days [14]. The challenge therefore is to reduce the time
from diagnosis to treatment, which can be due to either
programmatic or patient-related issues, or both.
Table 4 Time from diagnosis to treatment initiation (days)
Comparisons Number IQR (days) Median p-value
Time to treatment
Initiation (Days)
Culture 143 8–29 14
LPA 28 6.5–32.5 14.5
Xpert 114 8–23 15 0.9521
Total 285 8–27 14
LPA 28 6.5–32.5 14.5 0.8294
Xpert 114 8–23 15
LPA 28 6.5–32.5 14.5 0.7148
Culture 143 8–29 14
Xpert 114 8–23 15 0.9616
Culture 143 8–29 14
HIV Positive 175 7–27 14 0.5522




0.035 (−3.13 3.20) <0.0001 0.983
aA 10-year increase in age
Table 5 Time from sputum collection to treatment initiation
Comparisons Number IQR (days) Median p-value
Time to treatment
Initiation (days)
Culture 143 50–103 64 0.0001
LPA 28 14.5–53 29
Xpert 114 11–27 18
Total 285 20–69 49
LPA 28 14.5–53 29 0.0044
Xpert 114 11–27 18
LPA 28 14.5–53 29 <0.0001
Culture 143 50–103 64
Xpert 114 11–27 18 <0.0001
Culture 143 50–103 64
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Programmatic factors that impacted on the time from
diagnosis to treatment initiation in this study included the
following related to a centralized care model: all patients
had to be admitted to designated hospitals approximately
200 km outside of the sub-district for initiation of treat-
ment where they stayed until confirmed culture negative;
and logistical challenges contributed to delays e.g. avail-
ability of hospital beds and transportation.
Strengthening of health systems with innovative pro-
grams of care can improve outcomes including survival,
a high treatment rate (86% of those diagnosed), reduced
treatment delay, and improved case detection of MDR-
TB in South Africa [29, 30]. A systematic review and meta-
analysis concluded that community based MDR-TB treat-
ment programs globally were non-inferior to centralized
programs [31]. The South African Department of Health is
implementing a decentralised model of care [32].
The HIV prevalence (61%) in patients with MDR-TB
in this study is broadly similar to studies in South Africa
namely, Cape Town, 74% [19]; Cape Town, 59% [18];
Northern Cape Province, 67% [11]; and KwaZulu Natal,
71% [33]. People with HIV are at increased risk of MDR-
TB. with an odds ratio of 1.24 compared to HIV negative
people [34].
All patients diagnosed with HIV and MDR-TB were
on antiretroviral therapy (ART). As all patients were
hospitalised for initiation of MDR-TB treatment, it was
easy to ensure compliance with national guidelines which
state that patients with MDR-TB must be fast-tracked on
ART [5, 35]. The fact that 100% of HIV positive patients
were on ART means a working policy i.e. ART guidelines
are well implemented. ART is associated with improved
survival in patients with HIV and MDR-TB [36, 37].
In this study, there were significantly more males than
females with MDR-TB and HIV with a male to female
ratio of 1.4, similar to two South African studies where
the ratios were 1.2 [38] and 1.3 [18]. There were also
more male than female HIV negative patients with
MDR-TB, with a ratio of 1.2. Farley [38] also found a
higher male to female ratio of 1.7 in HIV negative
patients. The male to female ratio was 1.3 among all
patients diagnosed with TB in South Africa in 2014 [1].
The reasons for the male preponderance are not well
characterised but may reflect biological differences in
male and female susceptibility to TB infection and
disease [39].
A limitation of retrospective observational studies is
missing data. There are challenges with the EDRWeb
system including poor-quality data entry and the lack
of a unique patient identifier to track patient data
[40]. In this study, missing data were managed by
omitting patients from analysis (case deletion) as
opposed to data imputation which is typically used
with very large computerised databases [41].
Exclusion of patients with missing data from analysis
may have biased results. However, there was no reason
to suspect that patients with missing data differed in any
respect than those who were included. The time to
diagnosis and TTTI did not account for the time from
collection of sputum to registration at the laboratory. If
specimens arrive late in the day at the laboratory, they
would be analysed the next day. Thus, the time to
diagnosis and TTTI in this study may have been under-
estimated by approximately one day.
The strength of this study is that it analysed real
world clinical practice in a deprived rural sub-district
in South Africa and depicted high statistical power
and reliability due to the adequate sample. It is likely
that the results of this study are applicable in similar
rural settings in South Africa.
Conclusion
This study shows that Xpert reduces time to treatment
initiation in a rural setting with a median TTTI of
18 days. This is similar to TTTI’s in urban settings in
South Africa. However, to achieve the national target of
5 days, it is necessary to reduce the time from diagnosis
to treatment by addressing health system and patient-
related challenges contributing to delayed treatment
initiation.
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